Biolexis Therapeutics, an American Fork, UT-based clinical-stage AI-driven drug discovery company, closed a $10 million Series A funding.
SaaS Investors
The round was led by Clarke Capital.
Clarke Capital is an alternative asset investment firm with a robust portfolio of successful companies. Clarke takes a "hands on" approach when partnering with visionary entrepreneurs with an aim to create and grow high-potential, industry transformative companies.
Biolexis Therapeutics Use of Funds
The company will use the funding to advance its development pipeline, which includes metabolic drug candidates with the potential to address various metabolic disorders linked to health complications such as obesity and diabetes. The funding will support the company's mission to develop new and effective treatment options for metabolic diseases.
About Biolexis Therapeutics
Biolexis Therapeutics is a privately held clinical-stage biopharmaceutical company dedicated to developing small molecules targeting cancers, immune-mediated, neurodegenerative, auto-immune, metabolic, and inflammatory diseases. Biolexis uses its AI-driven MolecuLern process to identify novel chemical entities with drug-like characteristics, reducing the discovery and development timeline. Biolexis rapidly discovers and develops novel clinical candidates with unprecedented speed and accuracy through their proprietary MolecuLern AI-enabled drug discovery process. Using its unique AI-driven MolecuLern™ process, Biolexis has 40 active programs in discovery and 10 pipeline programs in the IND-enabling stages of development. The company’s mission is to map the interactions of chemicals and proteins to discover new products to benefit humanity.
Funding Details
Company: Biolexis Therapeutics, Inc.
Raised: $10.0M
Round: Series A
Funding Month: November 2023
Lead Investors: Clarke Capital
Additional Investors:
Company Website: https://biolexistx.com/
Software Category: AI-Drug Discovery
Source: https://www.prnewswire.com/news-releases/biolexis-secures-10-million-in-series-a-funding-to-advance-metabolic-drug-development-302000177.html